1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Nycomed Pharma AS in Consumer Health (Uzbekistan)

Nycomed Pharma AS in Consumer Health (Uzbekistan)

  • November 2015
  • -
  • Euromonitor International
  • -
  • 2 pages

Summary

Table of Contents

Search Inside

Nycomed started its activities in 1874 with the production of pharmaceuticals for Norway. One of the main products was aspirin. It was sold under the brand name Nycomed Globoid, widely known in Norway today. In 1959, Nycomed developed a contrast medicine, Izopak, through which the company became a major manufacturer of contrast visualisation products in the market. Based on the traditions of scientific and pharmacological studies, the company has further strengthened its position as a world...

Euromonitor International Local Company Profiles are a concise set of briefings detailing the strategic direction taken by a company. Discover key contact details, the company background and their competitive positioning through this collection of snapshot company profiles.


Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Consumer Health market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • March 2017
  • by GBI Research

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation Summary Head and neck cancer (HNC) is the sixth most common malignancy worldwide, ...

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential Summary Immunology is one of the largest therapy areas, with a total of 2,145 ...

Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends.  Price & Volume Forecasts by Laboratory Department. 2017 to 2022 -  Global Version

Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department. 2017 to 2022 - Global Version

  • $ 5995
  • Industry report
  • April 2017
  • by Howe Sound Research

“Medical Laboratory Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Overview: A market that just keeps on growing. ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.